- Home
- XXII vs ONCT Comparison
XXII vs ONCT Comparison
Compare XXII & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- ONCT
- Stock Information
- Founded
- XXII 1998
- ONCT N/A
- Country
- XXII United States
- ONCT United States
- Employees
- XXII N/A
- ONCT N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- ONCT Health Care
- Exchange
- XXII Nasdaq
- ONCT Nasdaq
- Market Cap
- XXII 4.0M
- ONCT 4.3M
- IPO Year
- XXII N/A
- ONCT N/A
- Fundamental
- Price
- XXII $0.09
- ONCT $1.13
- Analyst Decision
- XXII
- ONCT Buy
- Analyst Count
- XXII 0
- ONCT 3
- Target Price
- XXII N/A
- ONCT $10.00
- AVG Volume (30 Days)
- XXII 9.6M
- ONCT 157.5K
- Earning Date
- XXII 11-12-2024
- ONCT 11-06-2024
- Dividend Yield
- XXII N/A
- ONCT N/A
- EPS Growth
- XXII N/A
- ONCT N/A
- EPS
- XXII N/A
- ONCT N/A
- Revenue
- XXII $9,918,000.00
- ONCT $2,161,000.00
- Revenue This Year
- XXII $56.94
- ONCT $113.76
- Revenue Next Year
- XXII $2.98
- ONCT N/A
- P/E Ratio
- XXII $0.03
- ONCT N/A
- Revenue Growth
- XXII N/A
- ONCT 227.92
- 52 Week Low
- XXII $0.09
- ONCT $1.03
- 52 Week High
- XXII $5.28
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- XXII 31.38
- ONCT 37.09
- Support Level
- XXII $0.09
- ONCT $1.03
- Resistance Level
- XXII $0.13
- ONCT $1.30
- Average True Range (ATR)
- XXII 0.01
- ONCT 0.19
- MACD
- XXII 0.01
- ONCT -0.01
- Stochastic Oscillator
- XXII 10.51
- ONCT 13.70
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.